Cited 4 times in
Association between Inhaled Corticosteroid Use and SARS-CoV-2 Infection: A Nationwide Population-Based Study in South Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정지예 | - |
dc.date.accessioned | 2022-03-11T05:46:34Z | - |
dc.date.available | 2022-03-11T05:46:34Z | - |
dc.date.issued | 2022-01 | - |
dc.identifier.issn | 1738-3536 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/187784 | - |
dc.description.abstract | Background: Although it is known that inhaled corticosteroid (ICS) use may increase the risk of respiratory infection, its influence on the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remains unknown. Thus, the aim of this study was to investigate the association between ICS use and the positivity of SARS-CoV-2 infection among patients with chronic respiratory diseases. Methods: Nationwide data of 44,968 individuals with chronic respiratory diseases tested for SARS-CoV-2 until May 15, 2021 were obtained from the Ministry of Health and Welfare and Health Insurance Review and Assessment Service in Korea. The positivity of SARS-CoV-2 infection was retrospectively analysed according to the prescription, type, and dose of ICS taken one year before SARS-CoV-2 test. Results: Among 44,968 individuals tested, 931 (2.1%) were positive for SARS-CoV-2. A total of 7,019 patients (15.6%) were prescribed ICS one year prior to being tested for SARS-CoV-2. Low, medium, and high doses of ICS were prescribed in 7.5%, 1.6%, and 6.5% of total cases, respectively. Among types of ICS, budesonide, fluticasone, beclomethasone, and ciclesonide were prescribed in 3.7%, 8.9%, 2.3%, and 0.6% of total cases, respectively. A multivariate analysis showed no significant increase in infection with ICS use (odds ratio, 0.84; 95% confidence interval, 0.66-1.03). Moreover, there were no associations between the positivity of infection and the dose or type of ICS prescribed. Conclusion: Prior ICS use did not increase the positivity for SARS-CoV-2 infection. Moreover, different doses or types of ICS did not affect this positivity. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | Korean | - |
dc.publisher | 대한결핵 및 호흡기학회 | - |
dc.relation.isPartOf | TUBERCULOSIS AND RESPIRATORY DISEASES | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Association between Inhaled Corticosteroid Use and SARS-CoV-2 Infection: A Nationwide Population-Based Study in South Korea | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Sang Chul Lee | - |
dc.contributor.googleauthor | Kang Ju Son | - |
dc.contributor.googleauthor | Chang Hoon Han | - |
dc.contributor.googleauthor | Ji Ye Jung | - |
dc.contributor.googleauthor | Seon Cheol Park | - |
dc.identifier.doi | 10.4046/trd.2021.0102 | - |
dc.contributor.localId | A03735 | - |
dc.relation.journalcode | J02761 | - |
dc.identifier.eissn | 2005-6184 | - |
dc.identifier.pmid | 34844402 | - |
dc.subject.keyword | Chronic Respiratory Diseases | - |
dc.subject.keyword | Inhaled Corticosteroid | - |
dc.subject.keyword | Risk | - |
dc.subject.keyword | Severe Acute Respiratory Syndrome Coronavirus 2 | - |
dc.contributor.alternativeName | Jung, Ji Ye | - |
dc.contributor.affiliatedAuthor | 정지예 | - |
dc.citation.volume | 85 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 80 | - |
dc.citation.endPage | 88 | - |
dc.identifier.bibliographicCitation | TUBERCULOSIS AND RESPIRATORY DISEASES, Vol.85(1) : 80-88, 2022-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.